Crinetics Pharmaceuticals Inc Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Tyler Van Buren - TD Securities LLC - Analyst : It's great to be back in coverage of Crinetics here again and congratulations on all of your achievements. Marc, I wish you the best. I want to ask about paltu. The data with paltu and acromegaly are clearly strong and the likelihood of approval in September is very high, but expectations for the launch seem conservative or even modest from some of your investors. So can you elaborate on the ongoing launch preparations for paltu? What might surprise people and your global strategy in particular?

Question: Joseph Schwartz - Leerink Partners LLC - Analyst : And congrats on all the progress. I was wondering if you could talk about the strategies you're working on to motivate acromegaly patients to see their health care providers, such as those in the community, we heard you say often lag in the uptake of new treatments. And in a related sense, how long do you think Phase III enrollment for atumelnant in CAH may take, recognizing that there's a new treatment option for the first time in a long time and could be a bit competitive. But also, I think you've already had a lot of experience with clinical development now for paltusotine. So I'm just wondering relative to that Phase III enrollment time line. How should we think about how long it might take for atumelnant in Phase III?

Question: Jessica Fye - JPMorgan Securities LLC - Analyst : I was curious if there's any update on where things stand with the open-label extension for the CAH Phase II trial. I'm just trying to think about if that's something we could see data from prior to getting those Phase III results. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 27, 2025 / 9:30PM, CRNX.OQ - Q4 2024 Crinetics Pharmaceuticals Inc Earnings Call

Question: Katherine Dellorusso - LifeSci Capital - Analyst : This is Kate on for Cory. Congratulations on the amazing progress this year. Just one from us related to the CAH program. It's, of course, still early days. But it seems like the carcinoid launch in CAH has gotten some early momentum. And we're just curious what were the learning you've taken from the launch thus far and how you might be considering that for atumelnant in the future? And is there anything thus far that surprised you?

Question: Gavin Clark-Gartner - Evercore Group LLC - Analyst : Congrats on the progress. For atumelnant, can you share any additional details on Cohort 4 in the TouCAHn study? And when we may be able to possibly see that data?

Question: Catherine Okoukoni - Citizens JMP Securities, LLC - Analyst : This is Catherine on for John. I have a follow-up question on CAH as well. I know that you just mentioned that you're going to be discussing the design details of the Phase III program going forward. But just a general question on the endpoint and a differentiated endpoint from the one that was previously used. So what is the rationale from a regulatory standpoint as well as a commercial standpoint on changing up the endpoint, if you could give a little bit more color on that?

Question: Dennis Ding - Jefferies LLC - Analyst : We just had one on atumelnant. Can you -- from a timing perspective, can you commit to sharing additional data this year, whether it's from CAH 14 or longer-term extension data or Cushing's? And then for the long-term extension, how do you think efficacy would evolve with longer treatment?

Question: Dennis Ding - Jefferies LLC - Analyst : Just around the long-term extension and how do you think efficacy could evolve if patients are on. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 27, 2025 / 9:30PM, CRNX.OQ - Q4 2024 Crinetics Pharmaceuticals Inc Earnings Call

Question: Catherine Novack - Jones Trading - Analyst : My question is around how are you prioritizing the three non-oncology assets that you're moving forward into IND filing this year? If you had to pick, which indication is most exciting to you at this time?

Question: Rohan Mathur - Oppenheimer & Co. Inc. - Analyst : This is Rohan on for Leland Gershell. Just one for me on paltusotine. Just given the use of adrenal steroidogenesis and acromegaly in patients with neuroendocrine tumors. How do you think about carcinoid from a commercial standpoint as there may be some overlapping call points and complementary dynamics once it's potentially made available in both indications?

Question: Andy Chen - Wolfe Research Securities - Analyst : I think it was Isabel, during the prepared remarks that mentioned that payers are very supportive of the value proposition of paltusotine. Can you discuss which features of the product they are the most excited about? So especially now that we know that Cipla will be back to the US market against Ipsen in this quarter? And then I hear that generics will launch in Europe in the second quarter. Wouldn't payers be more excited about those generics a lot more? Or do you think those are just basically nonfactors in the grand scheme of things? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 27, 2025 / 9:30PM, CRNX.OQ - Q4 2024 Crinetics Pharmaceuticals Inc Earnings Call

Question: Charles Moore - Robert W. Baird & Co., Inc. - Analyst : This is Charlie on for Brian. Just touching on the PTH antagonist. It would be great if you could tell us more about the landscape there in terms of how patients are usually treated as well as what you believe the antagonist could offer over that as well as when you think about the 200,000 incident cases. How many of those would you expect to be addressable with this compound?